Foamix Pharmaceuticals (FOMX) Shares Gap Up to $4.59

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $4.13, but opened at $4.59. Foamix Pharmaceuticals shares last traded at $4.70, with a volume of 19849 shares traded.

Several equities analysts have recently issued reports on FOMX shares. HC Wainwright set a $11.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 8th. Cantor Fitzgerald started coverage on shares of Foamix Pharmaceuticals in a research note on Thursday, October 11th. They issued an “overweight” rating on the stock. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Wednesday, September 19th. BidaskClub cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Finally, Cowen set a $30.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Foamix Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $13.69.

The company has a market capitalization of $240.97 million, a PE ratio of -2.51 and a beta of 2.10.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.07). The business had revenue of $0.87 million during the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 148.15% and a negative net margin of 2,049.92%. Equities analysts forecast that Foamix Pharmaceuticals Ltd will post -1.64 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP increased its position in shares of Foamix Pharmaceuticals by 205.6% in the third quarter. Trexquant Investment LP now owns 34,950 shares of the specialty pharmaceutical company’s stock worth $200,000 after acquiring an additional 23,515 shares in the last quarter. Senzar Asset Management LLC purchased a new position in shares of Foamix Pharmaceuticals in the second quarter worth approximately $338,000. ARK Investment Management LLC increased its position in shares of Foamix Pharmaceuticals by 17.7% in the second quarter. ARK Investment Management LLC now owns 106,243 shares of the specialty pharmaceutical company’s stock worth $532,000 after acquiring an additional 15,980 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Foamix Pharmaceuticals by 31.7% in the third quarter. Wells Fargo & Company MN now owns 132,900 shares of the specialty pharmaceutical company’s stock worth $761,000 after acquiring an additional 32,013 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its position in shares of Foamix Pharmaceuticals by 7.0% in the second quarter. Handelsbanken Fonder AB now owns 390,000 shares of the specialty pharmaceutical company’s stock worth $1,954,000 after acquiring an additional 25,500 shares in the last quarter. 47.01% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Foamix Pharmaceuticals (FOMX) Shares Gap Up to $4.59” was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.wkrb13.com/2018/11/10/foamix-pharmaceuticals-fomx-shares-gap-up-to-4-59.html.

About Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Featured Story: Retained Earnings

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply